Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV
Jake A. Ruddy, Brian J. Boyarsky, William A. Werbel, Justin R. Bailey, Andrew H. Karaba, Jacqueline Garonzik‐Wang, Dorry L. Segev, Christine M. Durand
Abstract
In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.
Topics & Concepts
VirologyMedicineCoronavirusAntibodyImmunologyRespiratory systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirusInternal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies